Learn more about our client results in our case summaries
TECHNOLOGY DEVELOPMENT – RENAL CARE
Product development and clinical stage supply chain roadmap serving tissue based vascular drug device for renal therapy.
OPERATIONS RESTRUCTURE – AESTHETICS PORTFOLIO
Restructure contract manufacture alliance, Quality System governance and end-to-end process efficiency
PROGRAM DEVELOPMENT – STRUCTURAL HEART/TAVI
Structural Heart R&D/CRO program, organization and pilot assessment supporting pre-market investment strategy.
COMMERCIAL READINESS – STRUCTURAL HEART/TAVI
Investor guidance on operational scale up and go to market readiness of Transcather Aortic Valve platform.
CONTROL STRATEGY – COMBINATION DRUG DEVICE
Benchmark gap assessment of Quality by Design controls and processes for consumer auto-inject combination drug devices.
TECHNOLOGY ASSESSMENT – STRUCTURAL HEART/TAVI
Investor guidance on “next generation” Transcather Aortic Valve development and go-to-market strategy.
ENDOVASCULAR TECHNOLOGY – INTERVENTIONAL NEUROLOGY
Quality System implementation, FDA Regulatory remediation and, interim leadership in robotic vascular access development.
INTELLECTUAL PROPERTY ARBITRATION – EU AESTHETICS
Favorable arbitral tribunal outcome thru defendant expert witness representation and technology IP evaluation.
OPERATIONS STRATEGY- NEUROVASCULAR THERAPY
CEO advisor on growth-driven business process re-engineering, leadership development, long term Operations strategy.
DUE DILIGENCE – STRUCTURAL HEART/TAVI
Advisor to APAC Private Equity Firm on assessment of alternative technologies suitable to emerging market needs.
Contact us for an initial assessment to help resolve complexity in your business operations. Our approach is designed to be client specific with a practical approach including an Introductory Consultation, Operational Assessment, Project Engagement and Verification of Sustainability.
